mamacrowd-logo
InvestRaiseFund&CrowdGuideNews
LoginSign up
Seffiline
Seffiline | Mamacrowd

Seffiline

Medical Devices

Devices for performing regenerative medicine therapies in a safe, simple, standardized and effective manner.

  • The regenerative therapy market is booming

  • Great dissemination potential for ease of use

  • Significant corporate assets of intellectual property

  • The devices can be used in many medical specialties

TAX Bonus

Innov STARTUP

    Project
    Team and Shareholders
    Market and Target
    Business Model
    Financial projections
    Use of funds
immagine copertina
The content of this page has been translated automatically

Project

Autologous regenerative therapy with adipose-derived mesenchymal stem cells has for years been a technology consideredcutting-edge and supported by enormous scientific production. In 2015, Prof. Alessandro Gennai published a surgical technique called S.E.F.F.I., which is receiving enormous interest in the surgical field because it greatly reduces the need for manipulation of harvested adipose tissue, thus safeguarding the viability of the cells to be implanted.

Some medical devices are already on the market, but they all have critical issues that do not allow their practical use except by highly qualified surgeons because they require experience in harvesting subcutaneous adipose tissue.

SEFFILINE was established in 2018 with the goal of making autologous regenerative therapy accessible to all physicians for application in various specialties. Through the invention of the guide, which was immediately patented, the goal is achieved.

In 2019, production and sale of the first and only medical device enabling autologous regenerative therapy through the use of mesenchymal stem cells of adipose origin begins. The device is all-in-one, disposable, standardized, safe and inexpensive, and can be used in medical clinics, without the need for an operating room and expensive machinery, by physicians of any specialty and without specific expertise in harvesting adipose tissue.

The regenerative potential of adipose-derived mesenchymal stem cells is extremely vast, enabling a variety of applications. Therefore, SEFFILINE has made medical devices that enable regenerative therapy in various fields:

  • Seffiller in Aesthetic Medicine for anti-aging facial treatment
  • Seffihair in Tricology for prevention and treatment of hair loss
  • Seffigyn in Gynecology for intimate well-being in childbearing and menopause and against genito-urinary syndrome
  • Sefficare in Orthopedics for the treatment of joint pathologies, including in sportsmen; in Vulnology for the treatment of sores and complex wounds; in Dermatology for the treatment of skin pathologies; and in other fields such as Vascular Surgery, Plastic Surgery, Urology, Colonproctology, and Otolaryngology to assist tissue regeneration.

SEFFILINE has entered into exclusive distribution agreements with minimum sales contractual constraints in the following countries: Italy, United Kingdom, Australia, New Zealand, United Arab Emirates and Saudi Arabia, Indonesia, Philippines and Thailand, Brazil while contacts are in place with Poland, Spain, Germany, France, Ukraine, Israel, Jordan, Mexico, Turkey, and Russia.

At present, most of the distributors are in the process of approving products in their respective countries and training agents. SEFFILINE, through its Academy, is in charge of the selection and training of trainers, medical opinion leaders and 'ambassadors' who train medical end-customers.

20210927190938_9c00ded7_Seffiline%20Slide%20Corredo%2002%201280x720

Want to find out more about this project?

Register or log in, if you already have an account, to view all information in detail

Sign up
Login

Seffiline

Medical Devices

Closed 09/12/2021
funded

Total funding

412.476 €

Goal min 150k €

Goal max 600,09k €

Professional Investor

Professional Inv.


73 investors

275% Goal min


Min order

499,84 €


Pre-Money

3Mln €

The information on the offer is not subject to approval by Consob. The Offering company is solely responsible for the completeness and truthfulness of the data and information provided by the latter. The investor's attention is also drawn to the fact that the investment, even indirect, through OICR or companies that invest mainly in financial instruments issued by innovative startups and SMEs is illiquid and characterised by a very high risk.
mamacrowd-logo

About us

Who we are

Press

Power User program

News

Carrers

Company informations

Real Estate Statistics

Crowdfunding services

Guide for the investor

Crowdfunding services

Investment costs

Risk warning

Alternative allowance regime

Tax benefits

Arbitrator for financial disputes

Dematerialized system

Trust company header service

Support

How to start

FAQ

Contacts

Terms & Conditions

Power User Terms & Conditions

Privacy Policy

Cookies Policy

Recovery Policy

Conflicts of Interest Policy

Handle Cookies

Warnings pursuant to art. 19 para. 2
the crowdfunding services provided by Mamacrowd do not fall under the deposit guarantee scheme established in accordance with Directive 2014/49/EU; the securities and instruments eligible for crowdfunding that can be acquired through this crowdfunding platform do not fall under the investor compensation scheme established in accordance with Directive 97/9/EC.

 

© 2025 Mamacrowd Srl a company of Azimut Group - VAT number IT07464370969 - Via Timavo 34, 20124 MI - SC € 95.417,54 fully paid up - Crowdfunding service provider authorised by resolution No. 22876 of 08/11/2023

  • Italiano

  • English

    Invest
      Invest in Startup/PMI and real estate projects
      Investor guide

    Raise
      Candidate a project

  • Italiano

  • English

Let us get to know you better

Mamacrowd and partners operate globally and can, upon acquiring your consent through the "Accept all", "Accept only necessary" or "Set preferences" commands, use cookies for statistical, advertising and also profiling purposes, own or third-party, to modulate the provision of the service in a personalized way and in line with your preferences.
In case of refusal we will only use the necessary cookies. For more information, read our Cookies Policy

Set preferences
Accept only necessary